CSF1R and Stroke: A study utilizing oral administration of PLX3397 to silence the CSF1R in rats prior to stroke reported that it exacerbated stroke severity and actually increased the infarct size at 3 days by increasing the production of inflammatory mediators by astrocytes (IL-1b, iNOS, IL-6).